R K Medicines Profile
Key Indicators
- Authorised Capital ₹ 1.25 Cr
- Paid Up Capital ₹ 1.24 Cr
- Company Age 37 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 17.67 Cr
- Satisfied Charges ₹ 47.35 Cr
- Revenue Growth -1.22%
- Profit Growth 39.73%
- Ebitda -144.73%
- Net Worth 11.50%
- Total Assets 32.94%
About R K Medicines
R K Medicines Private Ltd (RKMPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 10 June 1987 and has a history of 37 years and seven months. Its registered office is in Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.25 Cr and a paid-up capital of Rs 1.24 Cr.
The company currently has active open charges totaling ₹17.67 Cr. The company has closed loans amounting to ₹47.35 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sushasnt Sahu and Rajat Karanwal serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74899DL1987PTC028244
-
Company No.
028244
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Jun 1987
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at R K Medicines?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sushasnt Sahu
|
Director | 15-Feb-2020 | Current |
|
Rajat Karanwal
|
Director | 20-Dec-2019 | Current |
Financial Performance of R K Medicines.
R K Medicines Private Ltd, for the financial year ended 2023, experienced Minor drop in revenue, with a 1.22% decrease. The company also saw a substantial improvement in profitability, with a 39.73% increase in profit. The company's net worth Soared by an impressive increase of 11.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of R K Medicines?
In 2023, R K Medicines had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹17.67 Cr
₹47.35 Cr
Charges Breakdown by Lending Institutions
- Yes Bank Limited : 16.84 Cr
- Hdfc Bank Limited : 0.48 Cr
- State Bank Of India : 0.35 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 10 Jun 2024 | Hdfc Bank Limited | ₹1.45 M | Open |
| 31 Dec 2023 | Hdfc Bank Limited | ₹0.93 M | Open |
| 18 Oct 2023 | Yes Bank Limited | ₹16.84 Cr | Open |
| 13 Jan 2022 | Hdfc Bank Limited | ₹0.99 M | Open |
| 18 Jan 2021 | Hdfc Bank Limited | ₹1.48 M | Open |
How Many Employees Work at R K Medicines?
Unlock and access historical data on people associated with R K Medicines, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of R K Medicines, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped R K Medicines's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
